Article Information
History
- June 1, 2020.
Article Versions
- Version 1 (May 30, 2020 - 19:12).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Maxine Lamb1,
- Alexandra G Smith1,
- Daniel Painter1,
- Eleanor Kane1,
- Tim Bagguley1,
- Robert Newton1,2,
- Debra Howell1,
- Gordon Cook3,
- Ruth de Tute4,
- Andrew Rawstron4,
- Russell Patmore5 and
- Eve Roman1,*
- 1Department of Health Sciences, University of York, YO10 5DD, UK
- 2Ugandan Virus Research Institute, Entebbe, Uganda
- 3Department of Haematology, Leeds Cancer Centre, St James’s University Hospital, LS9 7LP, UK
- 4Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, St James’s University Hospital, LS9 7LP, UK
- 5Queens Centre for Oncology and Haematology, Hull University Teaching Hospitals NHS Trust, HU16 5JQ, UK
- ↵*Corresponding author: Eve Roman, Epidemiology & Cancer Statistics Group, Department of Health Sciences, Seebohm Rowntree Building, University of York, YO10 5DX, UK: eve.roman{at}york.ac.uk
Posted June 01, 2020.
Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort
